WALTHAM, Mass., Aug. 11 -- Thermo Electron Corp. announced today that it has purchased Ionalytics Corp., developer of a dynamic ion filtering device used with mass spectrometers in bioanalysis, proteomics and drug discovery. Financial terms were not disclosed.
Founded in 2001 as a spinoff of the National Research Council Canada, Ionalytics is based in Ottawa, Canada. Its customers consist of pharmaceutical development and manufacturing companies, as well as contract research organizations that assist major pharmaceutical companies in performing their bioanalytical measurements.
Marijn E. Dekkers, president and chief executive officer of Thermo Electron said, "Ionalytics has made significant strides in advancing the core technologies used in drug discovery, most notably a novel ion separation tool based on patent-protected FAIMS (high-field asymmetric waveform ion mobility spectrometry) technology. We believe that the addition of FAIMS will contribute tremendously to our customer's ability to push their detection limits, which is critical to accelerate drug discovery research. We will also continue to invest in several other promising initiatives currently underway at Ionalytics as we build the most comprehensive mass spectrometry portfolio in the world."
When combined with liquid chromatography mass spectrometry, FAIMS technology helps resolve analytical method development challenges significantly faster and more easily, Thermo Electron said. Based on this technology, Ionalytics created the Selectra, an ion separation tool intended to reduce chemical background noise, increase throughput and improve detection limits.
For more information, visit: www.thermo.com